- Home
- LGVN vs NXTC Comparison
LGVN vs NXTC Comparison
Compare LGVN & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGVN
- NXTC
- Stock Information
- Founded
- LGVN 2014
- NXTC 2015
- Country
- LGVN United States
- NXTC United States
- Employees
- LGVN N/A
- NXTC N/A
- Industry
- LGVN Medicinal Chemicals and Botanical Products
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- LGVN Health Care
- NXTC Health Care
- Exchange
- LGVN Nasdaq
- NXTC Nasdaq
- Market Cap
- LGVN 28.4M
- NXTC 31.6M
- IPO Year
- LGVN 2021
- NXTC 2019
- Fundamental
- Price
- LGVN $1.75
- NXTC $0.92
- Analyst Decision
- LGVN Strong Buy
- NXTC Strong Buy
- Analyst Count
- LGVN 3
- NXTC 2
- Target Price
- LGVN $8.67
- NXTC $4.00
- AVG Volume (30 Days)
- LGVN 325.0K
- NXTC 204.7K
- Earning Date
- LGVN 11-12-2024
- NXTC 11-07-2024
- Dividend Yield
- LGVN N/A
- NXTC N/A
- EPS Growth
- LGVN N/A
- NXTC N/A
- EPS
- LGVN N/A
- NXTC N/A
- Revenue
- LGVN $1,852,000.00
- NXTC N/A
- Revenue This Year
- LGVN $161.78
- NXTC N/A
- Revenue Next Year
- LGVN $40.89
- NXTC N/A
- P/E Ratio
- LGVN N/A
- NXTC N/A
- Revenue Growth
- LGVN 141.46
- NXTC N/A
- 52 Week Low
- LGVN $0.77
- NXTC $0.89
- 52 Week High
- LGVN $21.30
- NXTC $2.57
- Technical
- Relative Strength Index (RSI)
- LGVN 34.75
- NXTC 22.45
- Support Level
- LGVN $1.80
- NXTC $1.06
- Resistance Level
- LGVN $2.15
- NXTC $1.21
- Average True Range (ATR)
- LGVN 0.12
- NXTC 0.10
- MACD
- LGVN -0.02
- NXTC -0.02
- Stochastic Oscillator
- LGVN 4.42
- NXTC 2.58
About LGVN Longeveron Inc.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.